Frontiers Case report: Short-term eculizumab use in atypical HUS

Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.

Frontiers Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

PDF) Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort

Frontiers Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study, BMC Nephrology

PDF) Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome

PDF) A systematic review on the efficacy and safety of eculizumab for atypical hemolytic uremic syndrome

PDF) Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review - Parisi - 2021 - Brain and Behavior - Wiley Online Library

Frontiers Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

Frontiers Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

PDF) The use of eculizumab in gemcitabine induced thrombotic microangiopathy